Q2 EPS Estimates for Editas Medicine Raised by HC Wainwright

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Editas Medicine to -$0.32 from -$0.34, while keeping the company in loss territory for the rest of the forecast period as well.
• Analyst sentiment remains mixed but slightly favorable overall: Editas has a consensus rating of “Moderate Buy” with a $5.40 average target price, though recent calls ranged from buy upgrades to sell downgrades.
• Pipeline progress and financing remain the main story: the company reported encouraging preclinical data for EDIT-401 and expects clinical milestones in 2026, but a large public offering and the suspension of an ATM program highlight ongoing dilution and funding pressure.

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities researchers at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of Editas Medicine in a research report issued to clients and investors on Tuesday, May 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.32) per share for the quarter, up from their prior estimate of ($0.34). The consensus estimate for Editas Medicine's current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Editas Medicine's Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($1.04) EPS, Q1 2027 earnings at ($0.33) EPS, Q2 2027 earnings at ($0.33) EPS and Q4 2027 earnings at ($0.15) EPS.

EDIT has been the subject of a number of other reports. JonesTrading raised Editas Medicine from a "hold" rating to a "buy" rating and set a $8.00 price objective for the company in a report on Tuesday, March 10th. Robert W. Baird set a $6.00 target price on Editas Medicine in a report on Monday, March 9th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Editas Medicine in a report on Monday, April 20th. Chardan Capital upped their target price on Editas Medicine from $3.50 to $4.00 and gave the company a "buy" rating in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered Editas Medicine from a "hold" rating to a "sell" rating in a report on Sunday, May 10th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Editas Medicine presently has an average rating of "Moderate Buy" and a consensus target price of $5.40.

Editas Medicine Stock Performance

Shares of EDIT opened at $3.57 on Thursday. The stock has a 50 day moving average price of $2.83 and a two-hundred day moving average price of $2.43. The firm has a market capitalization of $349.54 million, a P/E ratio of -2.90 and a beta of 2.14. Editas Medicine has a 52 week low of $1.60 and a 52 week high of $4.54.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $6.37 million. Editas Medicine had a negative return on equity of 677.39% and a negative net margin of 281.59%.

Hedge Funds Weigh In On Editas Medicine

Several institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC lifted its stake in Editas Medicine by 30.7% in the first quarter. Renaissance Technologies LLC now owns 3,972,160 shares of the company's stock valued at $9,811,000 after purchasing an additional 932,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company's stock valued at $3,016,000 after purchasing an additional 1,430,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in Editas Medicine by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 2,284,740 shares of the company's stock valued at $4,685,000 after purchasing an additional 244,574 shares during the last quarter. State Street Corp lifted its stake in Editas Medicine by 2.6% in the fourth quarter. State Street Corp now owns 1,974,931 shares of the company's stock valued at $4,049,000 after purchasing an additional 49,887 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Editas Medicine by 63.3% in the third quarter. Two Sigma Investments LP now owns 1,584,155 shares of the company's stock valued at $5,497,000 after purchasing an additional 614,229 shares during the last quarter. Hedge funds and other institutional investors own 71.90% of the company's stock.

Key Editas Medicine News

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Investors showed strong speculative interest, with unusually heavy call buying suggesting some traders are positioning for further upside in Editas Medicine (EDIT).
• Positive Sentiment: HC Wainwright reiterated a bearish earnings outlook but the note did not materially worsen the company’s already negative profit profile, while keeping attention on future pipeline execution rather than near-term earnings.
• Positive Sentiment: Editas reported promising preclinical data for EDIT-401, showing ~90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates, which supports the drug’s potential in hyperlipidemia and cardiovascular risk reduction. Article Title
• Positive Sentiment: The company also said it is on track to submit a clinical trial notification by mid-2026 and expects early human proof-of-concept data by year-end, which may reinforce optimism around its lead program. Article Title
• Negative Sentiment: Editas priced an underwritten public offering of more than 55.5 million shares plus warrants, which is pressuring the stock because it increases dilution risk for existing shareholders. Article Title
• Negative Sentiment: The company also suspended and terminated a prior at-the-market offering program, underscoring its ongoing need to raise capital and highlighting financing overhangs. Article Title

Editas Medicine Company Profile

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine's research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company's pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.